Junichi Takada1, Satoshi Ikeda2, Tetsuya Kusanagi3, Satoshi Mizuno4, Hiroshi Wada5, Kousuke Iba6, Takashi Yoshizaki1, Toshihiko Yamashita6. 1. Kitago Orthopaedic Clinic, Sapporo, Hokkaido, Japan. 2. Department of Orthopaedic Surgery, Ken-Ai Memorial Hospital, Onga cho Fukuoka, Japan. 3. Kusanagi Ladies Clinic, Sapporo, Hokkaido, Japan. 4. Hanakawa Orthopaedic Clinic, Ishikari, Hokkaido, Japan. 5. Wada Women's Clinic, Asahikawa, Hokkaido, Japan. 6. Department of Orthopaedic Surgery, Sapporo Medical University, Sapporo, Hokkaido, Japan.
Abstract
OBJECTIVE: This study analyzes whether concomitant raloxifene (RLX) or bisphosphonates (BP) plus eldecalcitol (ELD) has excessive suppressive effects on a bone resorption marker during the first 6 months of treatment in postmenopausal women in real-world setting. METHODS: 285 postmenopausal osteoporotic patients who had been treated with RLX or BP plus ELD were evaluated the bone resorption marker, serum tartrate resistant acid phosphatase-5b (TRACP-5b), during the first 6 months of treatment. RESULTS: In drug-naïve group (not received osteoporosis medications before the administration, n=70), the concomitant RLX or BP with ELD significantly decreased levels of TRACP-5b without severe suppression. In vitamin D switch group [RLX or BP plus alfacalcidol (ALF) and then switched to RLX or BP plus ELD, n=215], the replacing ALF with ELD further and significantly decreased TRACP-5b and tertile analyses based on baseline values were significantly decreased far more in the highest, compared with the lowest tertile in the ELD+RLX and ELD+BP groups. CONCLUSION: ELD combined with RLX or BP administered for 6 months to postmenopausal women with osteoporosis who were drug-naïve or who had switched medications significantly reduced and maintained TRACP-5b values within the reference range.
OBJECTIVE: This study analyzes whether concomitant raloxifene (RLX) or bisphosphonates (BP) plus eldecalcitol (ELD) has excessive suppressive effects on a bone resorption marker during the first 6 months of treatment in postmenopausal women in real-world setting. METHODS: 285 postmenopausal osteoporoticpatients who had been treated with RLX or BP plus ELD were evaluated the bone resorption marker, serum tartrate resistant acid phosphatase-5b (TRACP-5b), during the first 6 months of treatment. RESULTS: In drug-naïve group (not received osteoporosis medications before the administration, n=70), the concomitant RLX or BP with ELD significantly decreased levels of TRACP-5b without severe suppression. In vitamin D switch group [RLX or BP plus alfacalcidol (ALF) and then switched to RLX or BP plus ELD, n=215], the replacing ALF with ELD further and significantly decreased TRACP-5b and tertile analyses based on baseline values were significantly decreased far more in the highest, compared with the lowest tertile in the ELD+RLX and ELD+BP groups. CONCLUSION: ELD combined with RLX or BP administered for 6 months to postmenopausal women with osteoporosis who were drug-naïve or who had switched medications significantly reduced and maintained TRACP-5b values within the reference range.
Authors: H Orimo; Y Hayashi; M Fukunaga; T Sone; S Fujiwara; M Shiraki; K Kushida; S Miyamoto; S Soen; J Nishimura; Y Oh-Hashi; T Hosoi; I Gorai; H Tanaka; T Igai; H Kishimoto Journal: J Bone Miner Metab Date: 2001 Impact factor: 2.626
Authors: S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller Journal: JAMA Date: 1999-10-13 Impact factor: 56.272
Authors: B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings Journal: JAMA Date: 1999-08-18 Impact factor: 56.272